Interleukin-1/-6 Inhibitors & Interstitial Lung Disease and Pulmonary Arterial Hypertension
Details
Regulatory Determination / Use
Feasibility assessment of ARIA to conduct a postmarket safety study. FDA decided that no action is necessary at this time, based on available information.